Characterization of the Natural History of LAMA2-RD and Identification of Novel Disease Biomarkers

Recruiting

• Conditions: LAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A); Merosin Deficient Congenital Muscular Dystrophy; LAMA2-MD \(Merosin Deficient Congenital Muscular Dystrophy, MDC1A\); Merosin Deficient CMD (Full or Partial)

• Registration Number: NCT07125040
• Lead Sponsor: Università Vita-Salute San Raffaele

Brief Summary

The goal of this observational study is to learn about the natural history and multi-organ involvement of Laminin-Alpha-2-Related Dystrophy (LAMA2-RD) in pediatric and adult patients. The main questions it aims to answer are:

* What is the prevalence and nature of cardiac involvement, and how do this relate to age and muscular phenotype?

* What is the prevalence of peripheral neuropathy, and how do this relate to age and muscular phenotype?

* What is the extent of respiratory, nutritional, skeletal, and cognitive/brain involvement, particularly in adults with more severe vs less severe phenotypes?

* How does quality of life and transition to adulthood occur in individuals with LAMA2-RD?

* Which nomenclature best reflects differences in disease severity and may support future clinical trial design?

Study participants will:

* Undergo retrospective and prospective clinical assessments every 12 months for 2 years across multiple centers.

* A subset of adult participants (n=20) will receive cardiac MRI with contrast enhancement.

* Provide biological samples during routine blood testing for future research.

Detailed Description

Background: LAMA2-RD is an autosomal recessive disorder due mutations in the LAMA2 gene. The clinical manifestations of LAMA2-RD range from severe, early-onset congenital muscular dystrophy (CMD) to a milder limb-girdle type muscular dystrophy (LGMDR23). A few promising therapies are getting closer to clinical application, but clinical trial readiness is limited by the paucity of natural history studies. Although some groups have recently shed light on different aspects of the disease, these are usually focused on pediatric populations. A detailed description of the disease in adult patients as well as the importance of specific organs involvement (e.g., heart and peripheral nervous system) are lacking.

Objectives: To describe the natural history of a large cohort of patients affected by LAMA2-RD (n=40-45).

Specifically, the investigators aim 1) to clarify the prevalence and characteristics of cardiac involvement, and to correlate the latter with age and muscular phenotype 2) to clarify the degree of neuropathic involvement 3) to clarify respiratory, nutritional, skeletal, and brain/cognitive involvement, with a focus on adult population 4) to clarify which nomenclature better captures differences in terms of disease severity, to help refine inclusion criteria for trials 5) to understand how quality of life is impacted and transition to adulthood performed 6) to collect biological material for future research Design and methods: This will be a multicenter, retrospective and prospective longitudinal observational study with additional procedures for a subset of patients: cardiac MRI with contrast enhancement and an additional sample handling during routine blood test. Patients will be assessed every 12 months over a period of 2 years. In addition to routine clinical assessments, cardiac MRI will be performed in a selected 20 adult population. The differential involvement of specific organs between LAMA2-RD subpopulations will be analyzed.

Study Timeline

• Study First Submitted: 2025-07-17
• Study Start: 2025-07-31
• Status Verified: 2025-08
• Study First Submitted QC: 2025-08-07
• Last Update Submitted: 2025-08-07
• Study First Posted: 2025-08-15
• Last Update Posted: 2025-08-15
• Primary Completion: 2027-05
• Study Completion: 2028-05-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Rhythm abnormalities	0, 12, 24 months	Prsence or absence of rhythm abnormalities (Brady arrhythmia, supraventricular and ventricular tachyarrhythmia) as detected by ECG and 24-hour Holter ECG
Cardiac function	0, 12, 24 months	Left ventricular end-diastolic volume (LVEDV) and left ventricular ejection fraction (LVEF) measured by transthoracic echocardiogram
Cardiac inflammation and fibrosis	T0	Cardiac inflammation and fibrosis by cardiac Magnetic Resonance Imaging (MRI) (only in adult patients)

Secondary Outcome Measures

Name	Time	Method
Motor outcome 1	0, 12, 24 months	The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) (0-2 years); maximum score 64
Motor outcome 2	0,12, 24 months	Motor Function Measure (MFM20 2-5 years; maximum score 60; MFM32 ≥ 5 years; maximum score 96)
Motor outcome 5	0, 12, 24 months	North Star Assessment for Limb-Girdle Type Muscular Dystrophies (NSAD); maximum score 54
Motor outcome 4 (Timed tests)	0, 12, 24 months	Timed rise from the floor (TRF) - seconds
Motor outcome 3 (Upper limbs)	0, 12, 24 months	Upper limbs function: Performance upper limb module 2.0. (PUL 2.0); maximum score 42
Respiratory function	0, 12, 24 months	Peak cough flow - PCF

Trial Locations

Locations (1)

Irccs Ospedale San Raffaele; 🇮🇹 Milan, Italy